Navigation Links
Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension

In rats with portal hypertension, ultraClow-dose aspirin has shown a normalizing effect of platelet-endothelial cell alterations and bleeding time. Further, this effect is mediated by Cyclooxygenase 2 inhibition.

This study, performed by a team led by Professor C. Doutremepuich, is described in a research article to be published in the October 14 issue of the World Journal of Gastroenterology.

Portal hypertension is a major complication of chronic liver disease, and bleeding is one of its most severe problems, leading often to death. Currently no treatment is used to modify the altered platelet activity observed in this pathology.

Ultra-low-dose aspirin has a prothrombotic effect that is the opposite of that observed with usual doses for the prevention of stroke or heart attack. The antithrombotic properties of low-dose aspirin are achieved by the inhibition of COX 1 in platelets. Aspirin is the most widely used antithrombotic agent. Previous research in rats has shown that the prothrombotic properties of ultra-low-dose aspirin are not mediated by platelets but by endothelial cells, and as such they have the potential of reversing the platelet-endothelial cell interaction alterations observed in portal hypertension.

In the view of the authors, to date no clear explanation has existed to elucidate the effect of such a small dose of aspirin, and no mechanism has been found to explain this contradictory action.

The prothrombotic effects of COX 2 inhibitors became evident in 2004 when one of the most widely accepted non-steroidal anti-inflammatory drugs was withdrawn from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Only aspirin has been demonstrated to have a prothrombotic effect at a very low dose.

In an elegant study design, including a model of in vivo Laser induced thrombosis in rats, bleeding time and prostanoid dosing, this research was performed by doctors from the Laboratory of Haematology of the Faculty of Pharmacy at the University of Bordeaux 2, France, Laboratoires Boiron and from the CEBBAD, Universidad Maimonides, Buenos Aires, Argentina.

Further research should explain the consequences of COX 2 inhibition produced by ultra-low doses of aspirin.


Contact: You-De Chang
World Journal of Gastroenterology

Related biology news :

1. Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy
2. Aspirin reduces cardiovascular risks in men and women -- but differently
3. Aspirin discovery may improve cancer treatments
4. Circles Of DNA Might Help Predict Success Of Stem Cell Transplantation
5. Antibiotic might fight HIV-induced neurological problems
6. Newly discovered pathway might help in design of cancer drugs
7. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
8. Compound might defeat African sleeping sickness, clinical trial beginning this month
9. Stem cells electric abilities might help their safe clinical use
10. Software might revolutionize glucose monitoring in critically ill patients
11. Free-radical busting antioxidants might not promote healthy hearts
Post Your Comments:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
Breaking Biology Technology: